SCHEDULE 13D/A: Galapagos NV and Gilead Announce Strategic Spin-off of Assets to Form New Biotech Entity, SpinCo

Galapagos NV and Gilead Sciences, Inc. have entered into a Separation Agreement to demerge certain assets and cash into a new entity, SpinCo, while Galapagos NV sharpens its focus on innovative cell therapies for cancer.

Summary

• Galapagos NV will separate a portion of its current cash balance and certain assets and liabilities into a new entity, 'SpinCo,' through a partial demerger under Belgian law.
• Existing shareholders of Galapagos NV will receive shares in SpinCo in the same proportion as their respective shareholdings in Galapagos NV.
• SpinCo's stated purpose is to identify and invest in building a pipeline of innovative medicines with robust proof of concept, initially focusing on oncology, immunology, and virology.
• Galapagos NV intends to restructure its existing business to reduce cash burn and concentrate its activities on developing and commercializing innovative cell therapies for the treatment of cancer.
• Gilead's existing warrant in Galapagos NV will be adjusted and split into a subscription right for shares of Galapagos NV ('BiotechCo Warrant') and a subscription right for shares of SpinCo ('SpinCo Warrant'), each allowing for up to 29.9% ownership.
• Employee Subscription Rights and Restricted Stock Units (RSUs) will also be adjusted and split between Galapagos NV and SpinCo.
• The Separation is contingent upon several conditions precedent, including obtaining relevant tax rulings from the Belgian tax administration, securing Euronext Brussels listing for SpinCo, and approval by an Extraordinary General Shareholders' Meeting (EGM) of Galapagos NV.
• The Separation is intended to be effective upon the completion of the Galapagos NV EGM approval, with a retroactive effect for accounting and tax purposes as of April 1, 2025.
• SpinCo will be incorporated as a Belgian 'naamloze vennootschap' (NV) and will have its own executive management team (3-4 persons) and a Board of Directors with a majority of Independent Non-Executive Directors.
• Gilead's right to appoint directors to Galapagos NV's Board of Directors will terminate upon the Separation Effective Time.
• Galapagos NV and Gilead Sciences, Inc. will enter into a new Royalty Agreement effective as of the Separation.
• Gilead will be subject to new standstill provisions regarding Galapagos NV shares until August 22, 2029, limiting its ownership to 29.9%, and a lock-up period on Galapagos NV shares until the earliest of certain conditions or March 31, 2027.
• SpinCo will provide Galapagos NV with a financing backstop facility of up to [***] (confidential amount) at the Separation Effective Time, unless Galapagos NV elects otherwise.

Sentiment

Score: 7

Explanation: The document outlines a clear strategic separation aimed at enhancing focus and potentially unlocking value for both entities. While some financial details are redacted, the overall tone is forward-looking and structured, indicating a well-planned corporate action. The defined roles and future directions for both Galapagos NV and SpinCo, along with Gilead's continued support and commitment to vote for the separation, suggest a positive strategic realignment. The risks mentioned are primarily procedural and regulatory, common for such complex transactions.

Positives

• The strategic separation allows Galapagos NV to sharpen its focus on innovative cell therapies for cancer, potentially leading to more efficient resource allocation and reduced cash burn.
• The creation of SpinCo provides a dedicated entity with a specialized management team to identify and invest in a new pipeline of innovative medicines across oncology, immunology, and virology, potentially unlocking new value.
• Existing Galapagos NV shareholders will receive shares in SpinCo, ensuring their participation in the potential growth and success of the new entity.
• Gilead's commitment to vote its shares in favor of the Separation signals strong partner support for the strategic realignment.
• The provision of a financing backstop facility from SpinCo to Galapagos NV offers financial support to the Company post-separation.

Negatives

• The specific financial amounts for the 'Initial SpinCo Capital Allocation' and the 'Backstop Facility Agreement' are redacted ([***]), limiting full transparency on the financial implications.
• The restructuring of Galapagos NV to reduce cash burn may imply previous operational inefficiencies or the necessity for significant cost-cutting measures.
• The termination of Gilead's right to appoint directors to Galapagos NV's board could reduce Gilead's direct governance influence on Galapagos NV post-separation.
• The standstill and lock-up provisions, while standard for such transactions, impose restrictions on Gilead's ability to freely trade or increase its stake in either company for specified periods.

Risks

• The Separation is subject to obtaining favorable tax rulings from the Belgian tax administration, and failure to secure these could prevent or delay the transaction.
• Approval by an Extraordinary General Shareholders' Meeting of Galapagos NV is a condition precedent, and a lack of shareholder support could hinder the Separation.
• While Euronext Brussels listing for SpinCo is a condition, NASDAQ listing is not guaranteed and is subject to 'commercially reasonable efforts,' potentially impacting SpinCo's market access and liquidity.
• The complex process of separating assets, liabilities, and employee incentives carries inherent risks of operational challenges, disputes, or unforeseen complications.
• SpinCo needs to become fully operationally ready, including obtaining necessary permits, setting up technology systems, and establishing bank accounts, which could face delays or unexpected costs.
• The formation of a new management team and board for SpinCo, while strategic, introduces risks associated with new leadership, team integration, and execution of a new business strategy.
• Unforeseen tax consequences could arise despite efforts to achieve tax neutrality, particularly given the retroactive accounting and tax effective date.
• The market's reaction to the demerger and the new strategic focus for both entities is uncertain and could lead to volatility or adverse impacts on share prices.

Future Outlook

The Separation Agreement outlines a clear future strategic direction for both Galapagos NV and the newly formed SpinCo. Galapagos NV will focus on innovative cell therapies for cancer, aiming to reduce cash burn. SpinCo is intended to build a pipeline of innovative medicines, with an initial investment focus on oncology, immunology, and virology, led by a specialized management team. The parties aim for SpinCo to be listed on Euronext Brussels and potentially NASDAQ, indicating a plan for independent operation and growth.

Management Comments

• The Parties' intention is that (i) SpinCo will identify and invest to build a pipeline of innovative medicines with robust, demonstrated proof of concept through one or more transactions; (ii) SpinCo's management team will bring unique experience in asset identification and company-building across the therapeutic landscape to accelerate development and bring transformative medicines to patients; and (iii) SpinCo's initial investment focus will be in oncology, immunology and virology.
• Furthermore, prior to the Separation, it is the intention that the Company shall carry out a restructuring of its existing business with a view to reduce its cash burn, and to focus its activities on developing and commercializing innovative cell therapies for the treatment of cancer.
• The Company and the Parent Investor intend to announce the Separation and other transactions as contemplated herein on or about the Agreement Date.
• It is the Parties current intention that, as of the Separation Effective Time, SpinCo shall be a Belgian tax resident company, subject to changes in operational, financial, market, regulatory, or other business conditions that may arise.
• It is agreed by the Parties that at the Separation Effective Time, it is intended that the executive management of SpinCo will consist of between 3 to 4 persons, that shall be engaged by SpinCo on a full-time basis and which shall be comprised of biotech executives with significant transaction and company-building experience.
• The Parties intend for all of the shares of SpinCo be admitted to trading and listing on the regulated market of Euronext Brussels upon completion of the Separation... and will use commercially reasonable efforts for the shares of SpinCo to be admitted to trading and listing on the national market of NASDAQ.

Industry Context

This strategic separation reflects a growing trend in the biotechnology and pharmaceutical sectors where larger companies or those with diverse pipelines opt to spin off specific assets or therapeutic areas into independent entities. This allows the parent company to sharpen its focus on core strengths (in this case, cell therapies for cancer for Galapagos NV) and potentially unlock value by allowing the spun-off entity (SpinCo) to pursue its own specialized investment and development strategy in areas like oncology, immunology, and virology. This move can attract specialized investors for each entity and optimize capital allocation, aligning with industry efforts to accelerate drug development and bring transformative medicines to patients more efficiently.

Management Changes

Corporate Governance

Related Party Transactions

• The Separation Agreement itself is a significant related-party transaction between Galapagos NV and Gilead (a major shareholder and collaborator).
• The assignment of the Subscription Agreement from Galapagos NV to SpinCo, and its subsequent amendment, constitutes a related-party transaction.
• The new Royalty Agreement to be entered into between Galapagos NV and Gilead Sciences, Inc. is a related-party transaction.
• The Backstop Facility Agreement, where SpinCo will provide financing to Galapagos NV, is a related-party transaction.

Stakeholder Impact

• **Shareholders (Galapagos NV)**: Will receive shares in SpinCo proportionally, potentially unlocking value and providing exposure to a new, focused biotech entity. Their investment in Galapagos NV will be in a company with a narrower, cell therapy focus.
• **Employees (Galapagos NV)**: The company will undergo a restructuring to reduce cash burn, which could imply workforce adjustments. Employee incentive plans (Subscription Rights, RSUs) will be adjusted and split between Galapagos NV and SpinCo, ensuring continuity of benefits.
• **Management (Galapagos NV)**: The executive and senior management will continue in their roles, but Gilead's board designees will resign, potentially altering board dynamics.
• **Management (SpinCo)**: A new executive management team and board will be established, creating new leadership opportunities.
• **Gilead Sciences, Inc. (Parent Investor)**: Will maintain significant influence and ownership potential in both Galapagos NV and SpinCo through adjusted warrants and new agreements, but with defined standstill and lock-up periods. Their strategic collaboration with Galapagos NV (OLCA) is being modified.
• **Customers/Patients**: The strategic focus on cell therapies for cancer by Galapagos NV and the new pipeline development by SpinCo in oncology, immunology, and virology could lead to new innovative medicines becoming available.
• **Creditors**: The allocation of assets and liabilities between Galapagos NV and SpinCo will impact the financial standing of each entity, which could be relevant for creditors. The backstop facility from SpinCo to Galapagos NV could provide financial stability.

Next Steps

• Galapagos NV will incorporate SpinCo as soon as practicable after the Agreement Date.
• Galapagos NV will prepare and file partial demerger proposals and reports with competent enterprise courts and statutory auditors for both Galapagos NV and SpinCo.
• Galapagos NV will prepare Listing Documentation and make Listing Filings for SpinCo's Euronext Brussels and NASDAQ listings.
• Galapagos NV and SpinCo will take steps to obtain necessary tax rulings from the Belgian tax administration.
• Galapagos NV will inform and consult its personnel in due time in accordance with applicable labor laws regarding the Separation.
• Galapagos NV will cause SpinCo's Extraordinary General Shareholders' Meeting (EGM) to approve the Separation.
• Galapagos NV will convene an EGM to approve the Separation, and a subsequent EGM if the first is not quorate.
• Galapagos NV will appoint SpinCo Management in agreement with the Parent Investor, based on candidates proposed by the Parent Investor.
• Galapagos NV will identify, select, and recruit the SpinCo Board of Directors in agreement with the Parent Investor.
• Gilead Sciences, Inc. and Galapagos NV will concurrently enter into the Transfer Agreement on the Agreement Date.
• Gilead Sciences, Inc., Galapagos NV, and SpinCo will enter into the Novation Agreement on or about the Agreement Date.
• The relevant parties will execute an amended and restated Subscription Agreement reflecting the new provisions after the Agreement Date and prior to or concurrently with the Separation Effective Time.
• Galapagos NV and Gilead Sciences, Inc. will enter into the Royalty Agreement at the Separation Effective Time.
• Galapagos NV and SpinCo will agree on the Transitional Services to be provided by Galapagos NV to SpinCo during a reasonable transitional period after the Separation Effective Time.
• Galapagos NV will prepare SpinCo to be operationally ready as of, or promptly following, the Separation Effective Time, including obtaining permits, setting up technology systems, establishing bank accounts, and arranging independent lease arrangements.
• SpinCo will cease using Galapagos NV's intellectual property (name, mark, logo) and change its name.
• SpinCo and Galapagos NV will enter into a definitive agreement for the Backstop Facility Agreement at the Separation Effective Time, unless Galapagos NV elects otherwise.
• Galapagos NV will prepare a listing prospectus and use reasonable efforts to obtain a listing on the regulated markets of Euronext Brussels and Amsterdam for Gilead's shares in Galapagos NV within ninety (90) days following the Closing, or as soon as practicable if no prospectus is required.

Key Dates

Recommendation

Keywords

Galapagos NV, Gilead Sciences, Spin-off, Demerger, Biotechnology, Cell Therapy, Oncology, Immunology, Virology, Corporate Restructuring, SEC Filing, Schedule 13D/A, Strategic Separation, Warrant Adjustment, Shareholder Rights, Corporate Governance, Financial Reporting